Skip to main navigation Skip to search Skip to main content

Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants

  • Angelo Agathanggelou
  • , Victoria J. Weston
  • , Tracey Perry
  • , Nicholas J. Davies
  • , Anna Skowronska
  • , Daniel T. Payne
  • , John S. Fossey
  • , Ceri E. Oldreive
  • , Wenbin Wei
  • , Guy Pratt
  • , Helen Parry
  • , David Oscier
  • , Steve J. Coles
  • , Paul S. Hole
  • , Richard L. Darley
  • , Michael McMahon
  • , John D. Hayes
  • , Paul Moss
  • , Grant Stewart
  • , A. Malcolm R. Taylor
  • Tatjana Stankovic (Lead / Corresponding author)

    Research output: Contribution to journal › Article › peer-review

    Abstract

    Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. Hence, p53-independent strategies are required to target Ataxia Telangiectasia Mutated-deficient chronic lymphocytic leukemia. As Ataxia Telangiectasia Mutated has been implicated in redox homeostasis, we investigated the effect of the Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia genotype on cellular responses to oxidative stress with a view to therapeutic targeting. We found that in comparison to Ataxia Telangiectasia Mutated-wild type chronic lymphocytic leukemia, pro-oxidant treatment of Ataxia Telangiectasia Mutated-null cells led to reduced binding of NF-E2 p45-related factor-2 to antioxidant response elements and thus decreased expression of target genes. Furthermore, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia cells contained lower levels of antioxidants and elevated mitochondrial reactive oxygen species. Consequently, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia, but not tumours with 11q deletion or TP53 mutations, exhibited differentially increased sensitivity to pro-oxidants both in vitro and in vivo. We found that cell death was mediated by a p53- and caspase-independent mechanism associated with apoptosis inducing factor activity. Together, these data suggest that defective redox-homeostasis represents an attractive therapeutic target for Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia.

    Original languageEnglish
    Pages (from-to)1076-1085
    Number of pages10
    JournalHaematologica
    Volume100
    Issue number8
    Early online date3 Apr 2015
    DOIs
    Publication statusPublished - Aug 2015

    Fingerprint

    Dive into the research topics of 'Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants'. Together they form a unique fingerprint.

    Cite this